DVACIK 927066

DAVITA INC.

EDGAR filings

Customers

1 federal agency

Suppliers

5 disclosed

Top supplier share

100%

of American Realty Capital Healthcare Trust III, Inc. revenue · 3M to 2015-03-31

Top supplier by $

$59.0M

AKBA · FY to 2025-12-31

Federal obligations

$180.8M

FY2026 · USAspending.gov

Latest period

Dec 31, 2025

10-K filed 2026-03-26

Band height is the estimated dollar value: the disclosed share × the discloser's revenue for that period (latest full year where available) or federal dollars obligated. Each side is scaled on its own; dashed outlines are named without a figure. Click a band to open its source.

Suppliers 5

Companies that disclose DVA as a major customer, as a share of their own revenue. 5 active, 0 lapsed.

Company	% of their revenue	Est. $ from DVA	Period	Trend	Status	Source
American Realty Capital Healthcare Trust III, Inc. American Realty Capital Healthcare Trust III, Inc.	100%	$11.0K	3M 2015-03-31		Active	10-Q 2015-05-14
DaVita Healthcare Partners, Inc. 100% 10-Q filed 2015-05-14 Period 3M 2015-01-01 to 2015-03-31 (100%)Accession 0001609234-15-000007
AKBA Akebia Therapeutics, Inc.	25%	$59.0M	FY 2025-12-31		Active	10-K 2026-02-26
DaVita, Inc. 25 % * * 10-K filed 2026-02-26 Period FY 2025-01-01 to 2025-12-31 (25%)Accession 0001517022-26-000020 DaVita, Inc. 29 % 16 % 10-K filed 2026-02-26 Period FY 2024-01-01 to 2024-12-31Accession 0001517022-26-000020
NxStage Medical, Inc. NxStage Medical, Inc.	19%	$20.5M	3M 2018-09-30	±0.0pp	Active	10-Q 2018-11-07
DaVita 19 % 20 % 19 % 20 % 10-Q filed 2018-11-07 Period 3M 2018-07-01 to 2018-09-30 (19%), 3M 2017-07-01 to 2017-09-30 (20%)Accession 0001333170-18-000013 DaVita 19 % 20 % 19 % 20 % 10-Q filed 2018-08-07 Period 3M 2018-04-01 to 2018-06-30 (19%), 3M 2017-04-01 to 2017-06-30 (20%)Accession 0001333170-18-000010 DaVita 20 % 20 % 10-Q filed 2018-05-10 Period 3M 2018-01-01 to 2018-03-31 (20%), 3M 2017-01-01 to 2017-03-31 (20%)Accession 0001333170-18-000004 DaVita 20 % 20 % 20 % 10-K filed 2018-02-16 Period FY 2017-01-01 to 2017-12-31 (20%), FY 2016-01-01 to 2016-12-31 (20%), FY 2015-01-01 to 2015-12-31 (20%)Accession 0001333170-18-000002 DaVita 20 % 21 % 20 % 20 % 10-Q filed 2017-11-08 Period 3M 2016-07-01 to 2016-09-30 (21%)Accession 0001333170-17-000023 DaVita 20 % 20 % 20 % 20 % 10-Q filed 2017-08-08 Period 3M 2016-04-01 to 2016-06-30 (20%)Accession 0001333170-17-000016 DaVita 20 % 20 % 10-Q filed 2017-05-09 Period 3M 2016-01-01 to 2016-03-31 (20%)Accession 0001333170-17-000011 DaVita 21 % 20 % 20 % 20 % 10-Q filed 2016-11-03 Period 3M 2015-07-01 to 2015-09-30 (20%)Accession 0001333170-16-000043 DaVita 20 % 21 % 20 % 21 % 10-Q filed 2016-08-04 Period 3M 2015-04-01 to 2015-06-30 (21%)Accession 0001333170-16-000039 DaVita 20 % 21 % 10-Q filed 2016-05-04 Period 3M 2015-01-01 to 2015-03-31 (21%)Accession 0001333170-16-000028 DaVita 20 % 20 % 21 % 10-K filed 2017-02-28 Period FY 2014-01-01 to 2014-12-31 (21%)Accession 0001333170-17-000005 DaVita 21 % 21 % 21 % 22 % 10-Q filed 2015-08-06 Period 3M 2014-04-01 to 2014-06-30 (21%)Accession 0001193125-15-280189 DaVita 21 % 22 % 10-Q filed 2015-05-06 Period 3M 2014-01-01 to 2014-03-31 (22%)Accession 0001193125-15-174693 DaVita 20 % 21 % 21 % 10-K filed 2016-02-11 Period FY 2013-01-01 to 2013-12-31 (21%)Accession 0001333170-16-000025 DaVita 21 % 21 % 21 % 10-K filed 2015-02-26 Period FY 2012-01-01 to 2012-12-31 (21%)Accession 0001193125-15-064412
KERYX BIOPHARMACEUTICALS INC KERYX BIOPHARMACEUTICALS INC	Named	—	3M 2018-03-31	+8.0pp	Active	10-Q 2018-05-10
DaVita Rx 13 % — % 10-Q filed 2018-05-10 Period 3M 2018-01-01 to 2018-03-31Accession 0001114220-18-000050 DaVita Rx 18 % 10 % 10-K filed 2018-02-21 Period FY 2017-01-01 to 2017-12-31 (18%), FY 2016-01-01 to 2016-12-31 (10%)Accession 0001114220-18-000029 Davita Rx 17 % 10 % 10-Q filed 2017-05-04 Period 3M 2017-01-01 to 2017-03-31Accession 0001114220-17-000010 Davita Rx 24 % 19 % 10-Q filed 2016-04-28 Period 3M 2016-01-01 to 2016-03-31Accession 0001193125-16-563667 DaVita Rx 10 % 19 % 10-K filed 2018-02-21 Period FY 2015-01-01 to 2015-12-31 (19%)Accession 0001114220-18-000029 Davita Rx 19 % 11 % 10-K filed 2016-02-26 Period FY 2014-01-01 to 2014-12-31Accession 0001193125-16-481950
RMTI ROCKWELL MEDICAL, INC.	Named	—	FY 2025-12-31	—	Active	10-K 2026-03-26
DaVita represented 16% and 45% of net sales for the years ended December 31, 2025 and 2024, respectively. 10-K filed 2026-03-26 Period FY 2025-01-01 to 2025-12-31Accession 0001628280-26-021186

Federal contracts 1

Agencies that awarded contracts to this company, from USAspending.gov. Dollars are obligated amounts as reported, not estimates; $180.8M in the latest fiscal year shown per agency.

Agency	Obligated	Fiscal year	Awards	Trend	Largest award
Department of Veterans Affairs Department of Veterans Affairs	$180.8M	FY 2026	30	$252.3M → $2.2M → $535.5M → $180.8M	36C10G26K0197
EXPRESS REPORT: FY 26 NOVEMBER NDSC EXPRESS REPORT Award 36C10G26K0197 on USAspending.gov ↗ Largest of 30 awards in FY2026: $121.4M obligated

Unnamed major customers

Disclosed without names in the fiscal year ending 2016-12-31. Identities are not inferred.

Humana11%

Alerts are coming

Get an email when DVA's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.